Houlihan Lokey (HLI) Q2 2027 Earnings Call Transcript

Houlihan Lokey reported fiscal Q2 2027 revenue of $692 million, up 5% year over year, and adjusted diluted EPS of $1.85 versus $1.84 a year earlier. Corporate Finance revenue rose 10% to $481 million despite fewer closed transactions, while Financial Restructuring revenue fell 12% to $118 million; management expects a stronger second half and elevated restructuring revenue through fiscal 2028. The company repurchased approximately $50 million of shares and declared a $0.70-per-share quarterly dividend, while citing interest-rate and geopolitical volatility as risks.

Analysis

The earnings setup is better than the headline growth suggests, but the payoff is staggered: Corporate Finance recovery can support the next few quarters, while restructuring’s prospective upside is back-end loaded into calendar 2027–28. That creates a useful hedge within HLI’s business mix, not a near-term guarantee—the restructuring pipeline must convert into closed mandates, and management’s industry-cycle analogy is not a forecast of comparable revenue.

The less-discussed constraint is operating leverage. With compensation already targeted at a stable share of revenue, higher revenue should flow through more readily only if non-compensation growth moderates; recent expense growth and the Intrepid MD additions make integration and capacity costs worth tracking. Portfolio valuation provides a steadier earnings base, but its growth does not remove deal-cycle sensitivity elsewhere.

Near term, the market may reward confidence in stronger-than-usual second-half seasonality. Over 1–3 months, the key test is whether closed CF activity and fees sustain growth without relying on unusually favorable deal mix. Over 6–18 months, software-related restructuring and debt maturities are potential catalysts, but timing and conversion remain uncertain. Higher rates can widen restructuring demand while slowing M&A; the net effect depends on continued financing availability and clients’ willingness to close. The contrarian risk is treating management’s constructive pipeline commentary as realized earnings. Without current valuation and peer-multiple data, avoid an unconditional chase.

Key Decisions for Investors

• Consider a staged long in HLI on post-earnings weakness rather than buying an opening spike; the thesis is improving CF activity plus a later restructuring contribution. Check HLI’s current valuation against its own history and advisory peers before sizing—no price target is supported by the supplied data.
• Use the next quarter as the 1–3 month confirmation point: monitor CF revenue and transaction conversion, restructuring revenue/backlog commentary, and non-compensation expense growth. Reduce or exit if CF momentum reverses or expense growth continues to outpace revenue without improving earnings.
• Treat calendar 2027–28 software restructuring as a catalyst watch, not booked growth. Reassess if mandates fail to convert to closed transactions, management pushes out the expected revenue timing, or restructuring activity weakens despite debt-maturity pressure.
• Avoid assuming higher rates are uniformly positive: they may benefit restructuring while weighing on deal execution. Falsifiers include a material deterioration in financing availability, renewed deal delays from macro or geopolitical shocks, or a reversal in sponsor transaction activity.